Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Why Is Credit Suisse (CS) Stock Trending Today?

By Josh Enomoto, InvestorPlace Contributor

Troubled lender Credit Suisse sought to reassure its investors about its financial standing, which only caused more gyrations in CS stock.

7 Under-$20 Stock Picks to Beat the Market Slump

By Josh Enomoto, InvestorPlace Contributor

Although you typically get what you pay for, these stocks to buy under $20 confirm that even compelling ideas can go on discount.

META Stock: What to Know as Meta Platforms Freezes Hiring

By Josh Enomoto, InvestorPlace Contributor

Although Meta Platforms took the bold first step of announcing a restructuring initiative, mere cuts might not bolster META stock.

The 7 Best Micro-Cap Stocks to Buy Now

By Josh Enomoto, InvestorPlace Contributor

If you have the nerve and the patience, these incredibly risky names among the best micro-cap stocks just might deliver.

What Is Going on With Edesa Biotech (EDSA) Stock Today?

By Josh Enomoto, InvestorPlace Contributor

Edesa Biotech released encouraging Phase 2 results for its respiratory-syndrome-targeting antibody, thus initially boosting EDSA stock.

Load More